Bisphosphonate-induced osteonecrosis of the jaws: a literature review
Main Article Content
Abstract
Bisphosphonates are widely used, whether in osteoporosis or malignant bone disorders. Therefore, it is necessary that there is sufficient knowledge about the adverse effects of this drug, especially in relation to Osteonecrosis of the Jaws Developed by Bisphosphonates, which is a pathology generated in the gnathic bones. So, the following question was asked in the research problem: What is the current situation regarding the use of bisphosphonates and the onset of osteonecrosis of the jaw? Searches were carried out on digital library websites in search of articles and research in books by renowned authors. Inclusion and exclusion criteria for articles found were defined. The verification of each article was carried out so that it could have perspective and follow-up on the subject discussed. The following databases were used: PUBMED, BIREME and LILACS, and SCIELO between the years 2007 to 2019. It was concluded then that Bisphosphonates play a very important role as a cause of osteonecrosis of the jaws, where the prognosis will be worse if the patient is treated with intravenous rather than oral types.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Yagiela JA, Neidle EA, Dowd FJ. Farmacologia e Terapêutica para Dentistas. 6 ed. 2011:944.
Maahs MAP. Associação entre o uso de bisfosfonatos e osteonecrose dos maxilares: estudo em ratos. Pontifícia Universidade Católica do Rio Grande do Sul, 2008. Dissertação de Pós-Graduação em Odontologia.
Mendes JM. Bifosfonatos: Aspetos de segurança. Universidade Fernando Pessoa Faculdade de Ciências da Saúde, 2017. Dissertação de Mestrado em Ciências Farmacêuticas.
Yi S, Lee H, Lee J, Lee K, Kim J, Kim Y, Park J, Kim K. Bone Remodeling: Histone Modifications as Fate Determinants of Bone Cell Differentiation. International Journal of Molecular Sciences. 2019;20(13):31-47.
Giorgio I, Dell’Isola F, Andreaus U, Alzahrani F, Hayat T, Lekszycki T. On mechanically driven biological stimulus for bone remodeling as a diffusive phenomenon. Biomechanics And Modeling in Mechanobiology. 2019;18(6):1639-1663.
Sayilekshmy M, Hansen RB, Delaissé JM, Rolighed L, Andersen TL, Heegaard AM. Innervation is higher above Bone Remodeling Surfaces and in Cortical Pores in Human Bone: Lessons from patients with primary hyperparathyroidism. Scientific Reports. 2019;9(1):53-61.
Verselá B, Švandová E, Bobek J, Lesot H, Matalová E. Osteogenic and Angiogenic Profiles of Mandibular Bone-Forming Cells. Frontiers In Physiology. 2019;10(24):10-124.
Holstein SA. A patent review of bisphosphonates in treating bone disease. Expert Opinion on Therapeutic Patents. 2019;29(5):315-325.
Antoni CC, Matsumoto MA, Da Silva AA, Curi MM, Santiago Júnior JF, Sassi LM, Cardoso CL. Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. Brazilian Oral Research. 2018;32(23)23-32.
Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Brazilian Journal of Otorhinolaryngology. 2018;84(1):102-108.
Barin LM, Pillusky FM, Pasini MM, Danesi CC. Osteonecrosis of the jaws associated with bisphosphonates: a literature review. Rev. Odontol. Univ. 2016;28(2):126-134.
George EL, Truesdell SL, Magyar AL, Saunders MM. The effects of mechanically loaded osteocytes and inflammation on bone remodeling in a bisphosphonate-induced environment. Bone. 2019;127(1):460-473.
Jung J, Park JS, Righesso L, Pabst AM, Al-Nawas B, Kwon YD, Walter C. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro. Clinical Oral Investigations. 2018;22(7):2527-2534.
Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing?. Injury. 2016;47:65-68.
Koy S, Schubert M, Koy J, Ney M, Lauer G, Sabotowski R. Bisphosphonat-assoziierte Kiefernekrosen. Der Schmerz. 2015;29(2):171-178.
Gavalda C, Bagan JV. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. Medicina Oral Patología Oral y Cirugia Bucal. 2016;21(1):260-270.
Zhao T, Zhong W, Xiao S. Review of bisphosphonate related osteonecrosis of the jaws. Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery. 2016;30(7):589-592.
Bermúdez-Bejarano EB, Serrara-Figallo MA, Gutiérrez-Corrales A, Romero-Ruiz MM, Castillo-de-Oyagüe R, Gutiérrez-Pérez JL, Machuca-Portillo G, Torres-Lagares D. Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. Medicina oral, patologia oral y cirugía bucal. 2017;22(1):43-57.
Vermeer JAF, Renders GAP, Everts V. Osteonecrosis of the Jaw—a Bone Site-Specific Effect of Bisphosphonates. Current Osteoporosis Reports. 2016;14(5):219-225.
Shuster A, Reiser V, Trejo L, Ianculovici C, Kleinman S, Kaplan I. Comparison of the histopathological characteristics of osteomyelitis, medication-related osteonecrosis of the jaw, and osteoradionecrosis. International Journal of Oral and Maxillofacial Surgery. 2019;48(1):17-22.
Rodriguez-Lozano FJ, Oñate-Sanchez RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Medicina Oral Patología Oral y Cirugia Bucal. 2016;21(1):595-600.
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database of Systematic Reviews. 2016;(10):1-56.
El-Rabbany M, Sgro A, Lam KD, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related osteonecrosis of the jaw. The Journal of the American Dental Association. 2017;148(8):584-594.